We're hiring!
Adaptive Phage Therapeutics
Biotechnology
Gaithersburg, Maryland 5,038 followers
To save lives or restore health as a leader in safe, rapidly deployable, cost-effective cures for bacterial infections
About us
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.
- Website
-
http://www.aphage.com
External link for Adaptive Phage Therapeutics
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Gaithersburg, Maryland
- Type
- Privately Held
- Founded
- 2016
Locations
-
Primary
Get directions
22 Firstfield Rd
125
Gaithersburg, Maryland 20878, US
Employees at Adaptive Phage Therapeutics
Updates
-
Great article today in @Forbes on phage therapy and APT's efforts. Thanks Juergen Eckhardt and Kira Peikoff for this article and the spotlight on the critical need to advance phage therapy as a response to increasingly difficult to treat bacterial infections. Great photo of Steffanie Strathdee, Tom Patterson and her award winning 52kg fish! #phage #superbugs #fishing
-
Adaptive Phage Therapeutics reposted this
Last week marked the conclusion of my enriching summer internship journey with the Phage Hunting Division at Adaptive Phage Therapeutics (APT). These past 15 weeks have been transformative, both personally and professionally. I extend my heartfelt gratitude to the visionary leadership of the Phage Hunting Program, Waqas Chaudhry, Ph.D. for granting me this remarkable opportunity. Additionally, I wish to express my sincere appreciation to Ethan Snider, Marty L., and Viet Dang for their invaluable mentorship and guidance throughout this transformative research experience. Throughout the summer, I had the privilege of working closely with the dedicated scientists at APT, actively contributing to stage 2 clinical trials for prosthetic joint-replacement infections (PJI), Diabetic Foot Osteomyelitis (DFO), and Cystic Fibrosis-related Lung Infections. Simultaneously, I forged meaningful relationships with fellow interns, staff, and faculty, which added another layer of depth to my experience. APT's pioneering efforts in combating Multi-Drug Resistant Organisms (MROs) exposed me to a remarkable revelation – bacteriophages, with their potential to combat MROs, exist all around us, awaiting discovery and utilization. This experience has illuminated the true scope and potential impact of APT's research on the medical community. In closing, I extend my sincere gratitude to the entire APT team for granting me this invaluable opportunity. I would also like to extend my appreciation to our esteemed microbiologist, Ethan Snider, for his consistent support and mentorship during the summer. As I look ahead to my return to UMBC this fall, I eagerly anticipate applying the knowledge and insights acquired during this internship in my final year as an undergraduate researcher, furthering my journey toward becoming a physician-researcher. My resolve to excel and contribute significantly within the medical community has never been stronger.
-
-
APT was just named one of the best, most exciting and innovative private biotechs for 2023! Thanks Fierce Biotech for shinning a light on APT! “For the past 21 years, we have assessed hundreds of early-stage companies for inclusion in the 'Fierce 15' special report. To curate this list, we consider a diverse range of factors, including the robustness of their technology, partnerships, venture support and their competitive positioning within the market. Our special report celebrates innovation and creativity in the face of intense competition.” Ayla Ellison Editor-in-Chief Fierce Life Sciences and Healthcare #phage #adaptivephagetherapeutics #fierce https://lnkd.in/gTMkWDnh
Introducing Fierce Biotech's 2023 Fierce 15
fiercebiotech.com
-
The emergence of antimicrobial resistance (AMR) has turned once manageable diseases into immediate life-threatening challenges, leading to a global health crisis of alarming proportions. I'm delighted to announce that I had the opportunity to take part in Race Against Resistance: The life and death struggle to save antibiotics, a film produced by @BBCStoryWorks for the AMR Action Fund and funding partners Shionogi, Pfizer and Merck, which is set to launch on 5 September 2023. Watch now its captivating trailer to delve into this urgent global health emergency as we race against time to safeguard life-saving medicines and combat superbugs. #RaceAgainstResistance @BBC StoryWorks #phage https://lnkd.in/gbdphW8V
Race Against Resistance: The Life And Death Struggle To Save Antibiotics | Trailer | BBC StoryWorks
https://www.youtube.com/